Corcept Therapeutics Incorporated (CORT) Shares are Up 0.15%

On a relative basis, the stock has outperformed the S&P 500 by 23.07% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.15% in the last 1 week, and is up 22.41% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 9.45% and the 50-Day Moving Average is 12.1%.The 200 Day SMA reached 30.61%


Corcept Therapeutics Incorporated (NASDAQ:CORT): After opening at $6.3, the stock dipped to an intraday low of $6.26 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.55 and the buying power remained strong till the end. The stock closed at $6.5 for the day, a gain of 3.17% for the day session. The total traded volume was 580,965. The stocks close on the previous trading day was $6.5.

Corcept Therapeutics Incorporated (CORT) : The consensus price target for Corcept Therapeutics Incorporated (CORT) is $9.25 for the short term with a standard deviation of $3.4. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $12, however, the pessimist price target for the company is $5.

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Companys focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. It is developing mifepristone, a potent glucocorticoid receptor (GR) antagonist that modulates the activity of cortisol for the treatment of a number of severe metabolic, psychiatric and oncologic disorders. The Company also discovered three series of selective GR antagonists. As of December 31, 2014, it had commenced enrollment in a Phase I clinical study with CORT125134. The Company has completed Phase I trials of CORT108297 for the treatment of central nervous system disorders. The Companys product Korlym contains 300 milligram mifepristone for the treatment of hyperglycemia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.